Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $299.0 million.

  • Genmab A's Change in Accured Expenses rose 62926.83% to $299.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $392.0 million, marking a year-over-year increase of 22131.15%. This contributed to the annual value of $1.1 billion for FY2025, which is 11860.94% up from last year.
  • As of Q4 2025, Genmab A's Change in Accured Expenses stood at $299.0 million, which was up 62926.83% from $602.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Change in Accured Expenses registered a high of $602.0 million during Q3 2025, and its lowest value of -$28.0 million during Q3 2024.
  • In the last 3 years, Genmab A's Change in Accured Expenses had a median value of $80.0 million in 2024 and averaged $215.2 million.
  • Per our database at Business Quant, Genmab A's Change in Accured Expenses plummeted by 8801.17% in 2024 and then soared by 225000.0% in 2025.
  • Genmab A's Change in Accured Expenses (Quarter) stood at $342.0 million in 2023, then tumbled by 88.01% to $41.0 million in 2024, then soared by 629.27% to $299.0 million in 2025.
  • Its last three reported values are $299.0 million in Q4 2025, $602.0 million for Q3 2025, and $567.0 million during Q2 2025.